journal article·2014-02

Evaluation of mucoadhesive carrier adjuvant: Toward an oral anthrax vaccine

Sharad Mangal, Dilip Pawar, Udita Agrawal, Arvind K. Jain, Suresh P. Vyas

Publisher page

Abstract

The aim of present study was to evaluate the potential of mucoadhesive alginate-coated chitosan microparticles (A-CHMp) for oral vaccine against anthrax. The zeta potential of A-CHMp was -29.7 mV, and alginate coating could prevent the burst release of antigen in simulated gastric fluid. The results indicated that A-CHMp was mucoadhesive in nature and transported it to the peyer's patch upon oral delivery. The immunization studies indicated that A-CHMp resulted in the induction of potent systemic and mucosal immune responses, whereas alum-adjuvanted rPA could induce only systemic immune response. Thus, A-CHMp represents a promising acid carrier adjuvant for oral immunization against anthrax.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Viral gastroenteritis research and epidemiology · Bacillus and Francisella bacterial research · Probiotics and Fermented Foods

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (32)

Show source-provided references
1. Abramova FA · Proc Natl Acad Sci USA · 1993 · 90 · 229110.1073/pnas.90.6.2291 ↗
2. Berthold I · Vaccine · 2005 · 23 · 199310.1016/j.vaccine.2004.10.014 ↗
3. Bonferoni MC · Pharm Dev Technol · 1999 · 4 · 4510.1080/10837459908984223 ↗
4. Borges O · Int J Pharm · 2005 · 299 · 15510.1016/j.ijpharm.2005.04.037 ↗
5. 10.4049/jimmunol.170.11.563610.4049/jimmunol.170.11.5636 ↗
6. 10.1016/S0264-410X(02)00191-310.1016/S0264-410X(02)00191-3 ↗
7. Eldridge JH · I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release · 1990 · 11 · 205
8. Elson CO · J Immunol Methods · 1984 · 67 · 10110.1016/0022-1759(84)90089-9 ↗
9. Fellows PF · Vaccine · 2001 · 19 · 324110.1016/S0264-410X(01)00021-4 ↗
10. Gonzalez-Rodriguez ML · Int J Pharm · 2002 · 232 · 22510.1016/S0378-5173(01)00915-2 ↗
11. Grinberg LM · I. Quantitative microscopic findings. Mod Pathol · 2001 · 14 · 482
12. He P · Int J Pharm · 1998 · 166 · 7510.1016/S0378-5173(98)00027-1 ↗
13. Ivins BE · Vaccine · 1998 · 16 · 114110.1016/S0264-410X(98)80112-6 ↗
14. Jaganathan KS · Int J Pharm · 2005 · 294 · 2310.1016/j.ijpharm.2004.12.026 ↗
15. Jain S · J Pharm Pharmacol · 2006 · 58 · 30310.1211/jpp.58.3.0003 ↗
16. 10.1016/j.imlet.2005.04.00210.1016/j.imlet.2005.04.002 ↗
17. Lopez CR · STP Pharma Sci · 2000 · 10 · 69
18. 10.2174/15665241079106541710.2174/156652410791065417 ↗
19. 10.1016/j.vaccine.2011.04.11210.1016/j.vaccine.2011.04.112 ↗
20. Medina E · FEMS Immunol Med Microbiol · 2000 · 4 · 30510.1111/j.1574-695X.2000.tb01444.x ↗
21. Mishra N · Expert Opin Ther Pat · 2010 · 20 · 66110.1517/13543771003730425 ↗
22. Mosmann T · J Immunol Methods · 1983 · 5 · 5510.1016/0022-1759(83)90303-4 ↗
23. 10.1208/s12248-009-9169-110.1208/s12248-009-9169-1 ↗
24. Reuveny S · Infect Immun · 2001 · 69 · 288810.1128/IAI.69.5.2888-2893.2001 ↗
25. Rossi S · Pharm Dev Technol · 1999 · 4 · 55
26. 10.1081/DDC-10010518210.1081/DDC-100105182 ↗
27. Singh Y · J Biol Chem · 1989 · 64 · 1109910.1016/S0021-9258(18)60433-8 ↗
28. Smith MW · Exp Phys · 1995 · 80 · 73510.1113/expphysiol.1995.sp003882 ↗
29. Welkos S · J Med Microbiol · 2002 · 51 · 82110.1099/0022-1317-51-10-821 ↗
30. 10.1099/00221287-147-6-167710.1099/00221287-147-6-1677 ↗
31. Williamson ED · J Appl Microbiol · 1999 · 87 · 31510.1046/j.1365-2672.1999.00901.x ↗
32. Xu Y · Int J Pharm · 2003 · 250 · 21510.1016/S0378-5173(02)00548-3 ↗